Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
anticoagulant
Biotech
BMS-J&J blood thinner fails phase 3, denting blockbuster hopes
The partners stopped the phase 3 early for futility, closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales.
Nick Paul Taylor
Nov 14, 2025 8:10am
CSL pays $117M for option on phase 3 blood clotting specialist
Sep 16, 2025 4:31am
Novartis inks $925M Anthos takeover to rejoin clot-busting race
Feb 11, 2025 5:21am
Regeneron anticoagulant bests enoxaparin, matches Eliquis
Dec 19, 2024 8:50am
Blackstone's $250M bet beats Xarelto in phase 2 bleeding trial
Sep 18, 2023 6:00am
BMS, J&J's secondary stroke med doesn't stick the landing
Aug 28, 2022 3:36am
